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Standard immunosuppression is used in about 60% of patients receiving kidney grafts from
their  monozygotic twins living donor although an alloimmune response can not take place.
The  aim of the study was to asses the clinical response in patients receiving renal grafts
from  a monozygotic twin living donor when no immunosuppressive therapy is used.
Methods: This is a retrospective observational study of patients receiving kidney grafts from
their  monozygotic twins from 1969 to 2013. The following data were recorded: age, renal graft
recipient’s primary disease, renal function, renal survival and overall survival. Immunosup-
pressive therapy included a single intraoperative dose of methylprednisolone 500 mg and
no  maintenance immunosuppression.
Results: Five patients with kidney grafts from their monozygotic twins were dentiﬁed in
our  centre. Mean age at transplantation was 33 years (27–39). One-year overall survival and
graft  survival were 100%. Mean creatinine level was 0.96 ± 0.2 one year after transplanta
tion, and 1.2 ± 0.37 mg/dl at most recent follow-up. Two patients died with a functional graftfter kidney transplantation (causes were melanoma and cardiovascumore than 15 years alar  event respectively). Follow-up was lost in a patient one year after transplantation. Two
patients are alive with a functioning graft at 18 months and 42.5 years after transplantation
respectively.
DOI of original article:
http://dx.doi.org/10.1016/j.nefro.2015.06.006.
 Please cite this article as: Sánchez-Escuredo A, Barajas A, Revuelta I, Blasco M, Cofan F, Esforzado N, et al. Trasplante renal de donante
vivo  entre gemelos monocigotos sin inmunosupresión de mantenimiento. Nefrologia. 2015;35:358–362.
∗ Corresponding author.
E-mail addresses: asanchee@clinic.ub.es, asanchezescuredo@gmail.com (A. Sánchez-Escuredo).
2013-2514/© 2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
n e f r o l o g i a. 2 0 1 5;3  5(4):358–362 359
Conclusion: Kidney transplantation from a monozygotic twin living donor is associated with
excellent clinical outcomes. Immunosuppressive therapy to suppress alloimmune response
is  probably unnecessary if zygosity has been conﬁrmed.
© 2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Trasplante  renal  de  donante  vivo  entre  gemelos  monocigotos  sin
inmunosupresión  de  mantenimiento
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Monocigotos
r  e  s  u  m  e  n
Los pacientes trasplantados de rin˜ón de gemelo monocigótico reciben en un 60% de los casos
algún  tipo de inmunosupresión estándar a pesar de la imposibilidad teórica para generar
una  respuesta aloinmune. El objetivo de este estudio es evaluar la respuesta clínica de los
receptores renales de donante vivo de gemelo monocigoto sin tratamiento inmunosupresor.
Método: Estudio observacional retrospectivo entre 1969 y 2013 de pacientes trasplantados
renales de donante vivo entre gemelos monocigotos. Se ha recogido edad y enfermedad
primaria del receptor, función renal, supervivencia renal y global. El protocolo inmuno-
supresor consistía en la administración de una dosis única intraoperatoria de 500 mg  de
metilprednisolona sin otra inmunosupresión de mantenimiento.
Resultados: Se identiﬁcó a 5 receptores renales de gemelos idénticos en nuestro centro. Edad
media en el momento del trasplante 33 an˜os (27-39). La supervivencia a un an˜o de los
pacientes y el injerto fue del 100%. La creatinina media al an˜o fue de 0,96 ± 0,2 y al último
seguimiento de 1,2 ± 0,37 mg/dl. Dos pacientes fallecieron con injerto funcional más de 15
an˜os después del trasplante (uno debido a melanoma y otro debido a un evento cardio-
vascular). Se perdió el seguimiento de un paciente al an˜o del trasplante. Los 2 pacientes
restantes están vivos 18 meses y 42,5 an˜os después del trasplante, respectivamente, con
injerto funcionante.
Conclusión: El trasplante renal entre gemelos monocigotos ofrece excelentes resultados clíni-
cos.  Probablemente el tratamiento inmunosupresor para inhibir la respuesta aloinmune es
innecesario en estos casos cuando se haya comprobado la cigosidad.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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enal transplant from a living monozygotic twin donor,
hough uncommon, may be considered the ideal renal trans-
lant procedure, given the good renal and overall survival rates
t offers. It also offers the opportunity to minimise or stop
mmunosuppressive therapy.
In 1954, Murray et al. carried out the ﬁrst success-
ul renal transplant between monozygotic twins without
mmunosuppressive therapy.1 Following the success of that
ransplant, in the 1950s and 1960s, various case series were
escribed throughout the world with good renal survival.2–5
ubsequently, with the advent of modern immunosup-
ression in the 1970s, in order to avoid acute rejection
nd primary disease recurrence, patients with a transplant
rom a monozygotic twin donor started to receive main-
enance immunosuppressive therapy, despite the supposed
bsence of alloimmune response due to being monozygotic
wins.6,7 Currently, there are no randomised studies or clinicalguidelines that evaluate what type or dose of immunosuppres-
sion should be given in renal transplants from monozygotic
twins. There are reviews recommending the use of single-dose
methylprednisolone and the use of other immunosuppres-
sors for a short period.8 There are also case series of renal
transplants between monozygotic twins that minimised, or
did not give, immunosuppressive therapy, with good renal
outcome.9–12
To assess the need to administer or to stop mainte-
nance immunosuppressive therapy, it has been proposed that
patients undergoing this type of transplant have zygosity anal-
ysis using DNA analysis to establish the differences between
monozygotic twins (those that share 100% of their genetic
material) and dizygotic twins (those that share approximately
50% of their genetic material).13
The aim of this study was to evaluate the clinical
response of recipients of renal transplants from liv-
ing monozygotic twin donors, in transplants performed
at our centre without maintenance immunosuppressive
therapy.
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Methods
This was an observational retrospective study of living donor
renal transplants between monozygotic twins performed in
the Nephrology Department of Hospital Clínic de Barcelona,
between 1969 (the ﬁrst renal transplant performed in the hos-
pital) and 2013.
We identiﬁed 5 patients who had a renal transplant from
a living monozygotic twin donor. Clinical and analytical data
were collected at one year post-transplant and at most recent
follow-up. Monozygosity was not analysed with DNA tech-
niques, zygosity being assumed from HLA typing.
The 5 patients received a single dose of 500 mg  of
methylprednisolone in the operating theatre as immuno-
suppressive therapy. No other immunosuppressive treatment
was started. The patients did not receive prophylaxis against
cytomegalovirus.
Results
The mean age of the 5 recipients of renal transplant from an
identical twin was 27 years (range 20–39 years) at the time of
transplant. All patients shared blood group and 6 HLA identi-
ties with their donors. One patient had previously received a
transplant. The cause of end stage renal disease was not iden-
tiﬁed in 3 patients. One patient had membranoproliferative
glomerulonephritis and one patient (previously transplanted)
had interstitial nephropathy.
Patient survival and graft survival at 1 year were 100%.
Mean creatinine at 1 year was 0.96 ± 0.2 mg/dL. At 5 years, both
patient survival and renal survival were 100%. Mean creati-
nine was 1.2 ± 0.37 mg/dL. One patient died with a functional
graft (last creatinine 0.8 mg/dL) 16 years after the transplant,
due to malignant melanoma with multi-organ metastases,
aged 41 years. Another patient died aged 65 years due to a
cardiovascular event, 22.5 years after transplant (last creati-
nine 1.5 mg/dL). One patient was lost to follow-up at 1 year
with a functioning graft and creatinine of 1.2 mg/dL. The 2
Table 1 – Population characteristics.
Year of
transplant
Age at
RT
Primary renal
disease
Creatinine at
1 year
(mg/dL)
Protei
1 y
(mg
1969 30 Unknown origin 0.8 13
1975 20 Unknown origin 1.5 10
1977 25 MPGN 1 25
1981 23 Unknown origin 1.1 7
2011 39 Interstitial 1.3 23
MPGN: membranoproliferative glomerulonephritis; RT: renal transplant.;3 5(4):358–362
remaining patients were still alive at 18 months and 42.5 years
post-transplant, with functioning kidneys and serum creati-
nine of 1.2 mg/dL and 1.1 mg/dL, respectively (Table 1). The
last transplant patient had protocol biopsies at 3 months and
1 year, with no signs of cellular or humoral rejection. The
other patients did not have a biopsy because they had nor-
mal  renal function and protocol biopsies were not done at that
time. None of the 5 patients has had clinical acute rejection
and they have not received any further immunosuppressive
therapy during their follow-up.
Discussion
Our series of 5 cases of renal transplant between monozygotic
twins treated with intra-operative single-dose methylpred-
nisolone with no maintenance immunosuppression shows
good renal and overall survival without risk of developing
acute rejection or chronic humoral rejection.
Living donor transplantation represents a way to increase
preventative renal transplants and transplants for patients on
the waiting list, as it offers better renal survival and quality of
life, and is a cost-effective treatment.14 Currently, living donor
renal transplant makes up around 50% of all renal transplants
in some countries, and this percentage is increasing in coun-
tries such as Spain, which previously were performing mainly
cadaveric donor transplants.15
Various studies have shown that donation between
monozygotic twins is the best treatment option with excellent
renal and overall survival, but there is disagreement regard-
ing the immunosuppressive therapy they should receive.6,12
Kessaris et al. showed that in the United Kingdom more  than
50%, and in the USA more  than 2 thirds of patients with a renal
transplant from their identical twin were receiving long-term
immunosuppressive therapy.6 The authors explained that in
some patients, immunosuppression was given to prevent pri-
mary disease recurrence, despite the majority of patients not
having a primary renal disease at risk of recurrence. In the
survival analysis, patients with a theoretically elevated risk of
recurrence who did not receive immunosuppressive therapy,
nuria at
ear
/24 h)
Creatinine at
last follow-up
Proteinuria at
last follow-up
(mg/24 h)
Current
status 2014
1 1.1 121 Functioning graft
2 1.5 130 Died (22.5 years
post-RT with
functioning graft)
5 0.8 247 Died (16 years
post-RT with
functioning graft)
8 1.2 103 Follow-up in
different centre
(functioning
graft)
0 1.2 126 Functioning graft
1 5;3  5
h
r
N
o
i
s
w
t
1
i
t
b
g
o
d
a
r
a
m
T
b
r
i
i
i
c
c
d
I
a
l
w
s
p
d
S
m
a
i
w
n
u
f
c
p
t
t
i
a
k
d
s
i
p
t
g
l
r
1
1
1
1
1
1
1
1
1n e f r o l o g i a. 2 0 
ad no increased risk of primary disease recurrence. In the
eview by Krishnan et al. of the Organ Procurement Transplant
etwork database from 1987 to 2006, it was shown that 71%
f patients with a transplant from an identical twin stopped
mmunosuppressive therapy at 1 year, 33% continued with
ome type of immunosuppression, and 13% continued
ith standard triple therapy. In the survival analysis the group
hat stopped immunosuppression had better renal survival at
 year.12
Given the results obtained by other groups and our results,
t seems reasonable to propose reducing immunosuppression
o the absolute minimum in living donor renal transplants
etween identical twins. In the ideal situation of monozy-
otic twins, we propose giving an intra-operative single dose
f steroids with the aim of preventing ischaemia–reperfusion
amage. Damage from ischaemia–reperfusion during surgery
ctivates various cytokines that can activate the immune
esponse despite complete HLA identity between the donor
nd recipient. It has also been described that ischaemia can
odify donor DNA and genetic expression post-transplant.16
herefore, we  suggest the use of intra-operative steroids to
lock the immune response at several levels and reduce the
isk of acute rejection. The potential beneﬁts of subsequent
mmunosuppressive therapy should be carefully evaluated
n patients with risk of primary disease recurrence, because
mmunosuppressive therapy, particularly with steroids and
alcineurin inhibitors, is associated with serious infectious,
ardiovascular, and oncological complications, as well as the
eleterious effect of calcineurin inhibitors on the graft.17,18
n our series, we  emphasise that we  have observed no
cute or chronic rejection as a long-term cause of graft
oss with the proposed immunosuppression model, but there
as 1 case of neoplasia, despite not being on immuno-
uppressive therapy. We  think that this neoplasm, 16 years
ost-transplant, was unrelated to the transplant, as the inci-
ence of this type of tumour is one of the most increasing in
pain.19
DNA analysis has been used, historically, to determine
onozygosity.20,21 Nowadays, monozygosity tests using DNA
nalysis are available and can be used to assess the need for
mmunosuppressive therapy and prevent graft rejection, or
hen there is a high risk of primary disease recurrence. Krish-
an et al. recommended pretransplant monozygosity analysis
sing DNA in saliva.12 A recent review proposed always per-
orming zygosity studies in twins, since 25% of dizygotic twins
an have complete HLA identity and so would falsely be
resumed monozygotic.22 The authors proposed multilocus
esting (analysing various loci from different chromosomes)
o identify a series of DNA fragments that are present in all
ndividuals, but which are highly variable, and which would
llow identiﬁcation of monozygotic twins. This technique is
nown as multilocus DNA ﬁngerprinting.
The greatest limitation of our series was that we  did not
etermine monozygosity between donors and recipients; we
imply analysed the blood group and HLA identities, estimat-
ng the possibility of monozygosity, because in the transplants
erformed before 2000, possible genetic variability was not
aken into account, and in the last transplant, the DNA ﬁn-
erprinting technique was not routinely performed in our
aboratory.
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In summary, living donor renal transplant between
monozygotic twins, though uncommon, can be considered
the ideal renal transplant, as it does not require maintenance
immunosuppressive therapy. Due to potential immune-
system activation, we recommend an intra-operative single
dose of steroids to prevent acute rejection, once monozygosity
has been demonstrated.
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